Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

24 results about "Receptor potential" patented technology

A receptor potential, also known as a generator potential, a type of graded potential, is the transmembrane potential difference produced by activation of a sensory receptor. A receptor potential is often produced by sensory transduction. It is generally a depolarizing event resulting from inward current flow. The influx of current will often bring the membrane potential of the sensory receptor towards the threshold for triggering an action potential. Receptor potential can work to trigger an action potential either within the same neuron or on an adjacent cell. Within the same neuron, a receptor potential can cause local current to flow to a region capable of generating an action potential by opening voltage gated ion channels. A receptor potential can also cause the release of neurotransmitters from one cell that will act on another cell, generating an action potential in the second cell. The magnitude of the receptor potential determines the frequency with which action potentials are generated, and is controlled by adaption, stimulus strength, and temporal summation of successive receptor potentials. Receptor potential relies on receptor sensitivity which can adapt slowly, resulting in a slowly decaying receptor potential or rapidly, resulting in a quickly generated but shorter lasting receptor potential.

Compositions and methods for mode-selective modulation of transient receptor potential vanilloid-1 (TRPV1)

PCT designated stageWO2026006328A1Organic chemistryHeterocyclic compound active ingredientsSelective modulationClinical trial
TRPV1 is an integral cation channel widely expressed in various tissues and involved in critical biological functions, such as thermosensation. It is polymodally activated by distinct stimuli, including chemical ligands, heat, and protons (pH). However, dozens of clinical trials targeting various types of TRPV1 -mediated pain have generally failed, primarily due to hyperthermia (increased body temperature). Meta-analysis of clinical data suggests that mode-selectivity is essential to realizing the therapeutic potential of TRPV1. TRPV1 is regulated allosterically, with vanilloids and other chemical ligands binding to the voltage-sensing-like domain (VSLD), resulting in the gating of the pore domain. Therefore, compositions and methods for modulating TRPV1 to treat human pathophysiologies, such as pain, are described herein.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA +1

Five-membered 3-aryloxyl-3-heteroaryl propylamine compound, and crystalline form and use thereof

UndeterminedES3075814T3ArylDisease
The present invention relates to a five-membered 3-aryloxy-3-heteroarylpropylamine compound, its crystalline form, and its use. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt or prodrug thereof, having the structure of Formula I. The compound, or the pharmaceutically acceptable salt or prodrug of the present invention, possesses excellent inhibitory function against the transient receptor potential (TPR) channel protein and good therapeutic function for TPR-associated diseases.
Owner:SHANGHAI LEADO PHARMATECH CO LTD (100 00)

Compounds for treatment of excitotoxicity

PCT designated stageWO2026060489A1Nervous disorderOrganic chemistrySensory potentialTRPC
The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.
Owner:NYRADA PTY LTD

3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof

A 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof are provided. Specifically, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, the compound having a structure of formula I is described. The compound, or pharmaceutically acceptable salt or prodrug thereof has an excellent inhibition function for a transient receptor potential channel protein (TPR), and has a good treatment function for diseases associated with the TPR.
Owner:SHANGHAI LEADO PHARMATECH CO LTD

Oral antagonist compositions for nicotine burning relief

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).
Owner:FERTIN PHARMA AS

Riboswitches for regulating gene expression and therapeutic methods of using the same

PCT designated stage expiredWO2024227074A9VectorsPeptide/protein ingredientsHeterologousEnzyme Gene
The present disclosure provides an expression cassette comprising from 5' to 3': (i) promoter, (ii) an upstream exon, (iii) an upstream intron, (iv) an alternatively spliced exon comprising a translation initiation sequence, (v) a downstream intron, (vi) a downstream exon, and (vii) a heterologous nucleic acid sequence. In some aspects, the upstream exon, the upstream intron, the alternatively spliced exon, the downstream intron, and the downstream exon, each comprise a portion of a gene selected from the group consisting of a Transient Receptor Potential Cation Channel Subfamily V Member 3 (TRPV3) gene, a Serine / Threonine Kinase 31 (STK31) gene, an Ubiquitin Specific Peptidase 25 (USP25) gene, a IK gene, a Testis Expressed 14, Intercellular Bridge Forming Factor (TEX14) gene, a General Transcription Factor IIB (GTF2B) gene, and a LY6 / PLAUR Domain Containing 3 (LYPD3) gene.
Owner:KRIYA THERAPEUTICS INC

Transient receptor potential vanilloid 6 inhibitors

PendingEP4638443A4Organic active ingredientsOrganic chemistrySensory potentialVanillic acid
The present invention relates to methods and uses of preventing or treating cancer The method or use may comprise administration of a cancer therapy together with a compound of Formula (I). In the compound of Formula (I) A is a substituted heteroaryl comprising at least one ring nitrogen; and D includes an optionally substituted: phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl or thienyl (or R3' and D together form a five or six membered ring). The compound of Formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The present invention also relates to pharmaceutical compositions and kits comprising a compound of Formula (I) and / or a chemotherapeutic agent.
Owner:UNIQUEST PTY LTD

Application of alkylamine compound

PendingCN121818599ANervous disorderAntipyreticTransient receptor potential channelPharmaceutical drug
The invention relates to application of alkylamine compounds. Specifically, the invention provides an application of a compound shown as a formula I, or an optical isomer thereof, or a raceme thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, the compound, or the optical isomer thereof, or the raceme thereof, or the solvate thereof, or the pharmaceutically acceptable salt thereof are used for preparing a pharmaceutical composition or a preparation, and the pharmaceutical composition or the preparation is used for (a) inhibiting transient receptor potential channel protein; (b) treating diseases related to transient receptor potential channel protein, in the formula, each group is defined as in the specification. (I).
Owner:NINGBO LIDAO PHARMACEUTICAL TECHNOLOGY CO LTD

Compositions and Methods for Treating Cardiovascular Diseases and Disorders

Disclosed herein are compounds and ligands, and compositions formed therewith, that treat insulin resistance-induced physiological disorders by modulating G-protein coupled receptor (GPCR) and transient receptor potential (TRP) ion channel activity. Also disclosed herein are methods for using the compositions to treat cardiovascular disorders, such as atherosclerosis.
Owner:OLFACTIVE AI INC

Transient receptor potential vanilloid 6 inhibitors

The present invention relates to a method for preventing or treating cancer and its use therefor. The method or use may include administering a cancer therapy together with a compound of Formula (I). In the compound of Formula (I), A is a substituted heteroaryl containing at least one ring nitrogen, and D includes optionally substituted phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, or thienyl (or R3' and D together form a 5- or 6-membered ring). The compound of Formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The present invention also relates to pharmaceutical compositions and kits containing the compound of Formula (I) and / or a chemotherapeutic agent. TIFF2026502807000127.tif30170
Owner:UNIQUEST PTY LTD

Compositions and Methods for Treating Endocrine Diseases and Disorders

Disclosed herein are compounds and ligands, and compositions formed therewith, which modulate insulin secretion, suppress appetite, and reduce body mass by activating G-protein coupled receptors (GPCRs), such as ectopic olfactory receptors, and transient receptor potential (TRP) ion channels. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes and obesity.
Owner:OLFACTIVE AL INC

Transient receptor potential vanilloid 6 inhibitors

The present invention relates, inter alia, to compounds, pharmaceutical compositions of the compounds, and uses of the compounds for inhibiting transient receptor potential channel family, vanilloid subfamily member 6 (TRPV6). The compounds are of formula (I), where A is a substituted heteroaryl containing at least one ring nitrogen, and D includes optionally substituted phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, or thienyl (or R3' and D together form a 5- or 6-membered ring). The compounds may be used to treat or prevent one or more of cancer, respiratory disease, ulcerative colitis, skin disorders, bone disease, hypocalcemia, and kidney calcium stones. TIFF2026502801000601.tif28170
Owner:UNIQUEST PTY LTD

Compounds for treatment of excitotoxicity

PendingUS20260152495A1Organic active ingredientsNervous disorderSensory potentialTRPC
The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.
Owner:NYRADA PTY LTD

Substituted propionic acid derivatives and uses thereof

PendingCN121824350AOrganic chemistryNervous disorderDiseaseTransient receptor potential channel
The invention relates to substituted propionic acid derivatives and uses thereof. Specifically, the invention provides an application of a compound as shown in a formula A, or an optical isomer or a raceme thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, the compound, or the optical isomer or the raceme thereof, or the solvate thereof, or the pharmaceutically acceptable salt thereof are used for preparing a pharmaceutical composition or a preparation, and the pharmaceutical composition or the preparation is used for (a) inhibiting transient receptor potential channel protein; (b) treating diseases related to transient receptor potential channel protein, in the formula, each group is defined as in the specification. A.
Owner:NINGBO LIDAO PHARMACEUTICAL TECHNOLOGY CO LTD

Use of anagalline a in the preparation of analgesic drugs

The application relates to application of anagirine A in preparation of analgesic drugs, and relates to an anagirine A compound separated from anagallis arvensis, which is an analgesic drug with inhibitory effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), voltage-gated potassium channel 1.2 (Kv1.2), voltage-gated potassium channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and voltage-gated calcium channel 2.1 (Cav2.1), and is specifically a drug for neuropathic pain, traumatic pain or inflammatory pain. The compound anagirine A in the application can be combined with multiple analgesic related target points, so that a synergistic effect is generated, the treatment effect is enhanced, and side effects and drug resistance are reduced.
Owner:XINJIANG TECH INST OF PHYSICS & CHEM CHINESE ACAD OF SCI +1

Polypeptides for treating parkinson's disease

The application discloses a kind of polypeptides for treating Parkinson's disease.In the application, it is first found that transient receptor potential M2 type (TRPM2) channel is more expressed in fragile DA neuron subgroup, and its expression amount is positively correlated with age in Parkinson's disease (PD) patient, and the mechanism of action is determined through rigorous experiment, i.e.TRPM2 channel is preferentially activated in ADE neuron through PARP-1 / PARG / ADPR axis, drives Mfn2 / Bcl-2 complex dependent mitochondrial superfusion, causes ADE neuron death.In addition, TRPM2 channel also drives MPTP treatment mouse SNc DA neuron susceptibility through Mfn2 / Bcl-2 mediation.Firstly, it is found that blocking PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 mediated DA neuron death pathway can prevent the death of induced pluripotent stem cell (iPSC) derived DA neuron specific to spontaneous Parkinson's disease (SPD) patient.As susceptible SNc DA neuron loss is the main symptom of PD, therefore, PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 pathway can become a new therapeutic target for PD.
Owner:ZHEJIANG UNIV

Transient receptor potential cation channel, subfamily v, member 3 (trpv3) inhibitors and uses thereof

This invention belongs to the field of pharmaceutical technology, specifically relating to a transient receptor potential cation channel (TRPV3) inhibitor and its uses. The compound provided by this invention can act as a TRPV3 inhibitor, suppressing the abnormal increase in calcium ion influx caused by TRPV3 activation. It can effectively treat and prevent TRPV3-related conditions, providing new approaches for conditions such as itching, hair loss, atopic dermatitis, psoriasis, and ulcerative colitis. The compound provided by this invention exhibits better solubility while maintaining a comparable inhibition rate of calcium ion influx. Furthermore, the compound of this invention shows an inhibitory effect on the proliferation of human hepatic stellate cells (LX-2), demonstrating anti-fibrotic activity.
Owner:SUZHONG PHARMACEUTICAL GROUP CO LTD +1

Therapeutical tools and methods using temperature-sensitive receptors for treating blindness

The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contacting said retina with a nanomaterial conjugated to a molecule specifically binding to said extracellular tag, wherein said nanomaterial generates heat by absorbing radiations of a specific wavelength. And reagents therefor.
Owner:NOVARTIS FORSCHUNGSSTIFTUNG ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH +1

N-substituted phenylsulfonamide compounds and their uses

ActiveCN117529474BNervous disorderOrganic chemistryPhenylsulfonamideTransient receptor potential channel
This invention relates to N-substituted phenylsulfonamide compounds and their uses. Specifically, this invention provides a compound of formula I, or an optical isomer thereof, or a racemic mixture thereof, or a pharmaceutically acceptable salt thereof. The compound of this invention exhibits excellent inhibitory activity against transient receptor potential channel proteins and excellent therapeutic effects on diseases related to transient receptor potential channel proteins, such as inflammatory bowel disease, irritable bowel syndrome, pain, and inflammation.
Owner:SHANGHAI LEADO PHARMATECH CO LTD

Compounds for cancer treatment

PCT designated stageWO2026060487A1Organic active ingredientsOrganic chemistryTRPCOncology
The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels and the polymerization of tubulin, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions, such as cancer, using such modulators.
Owner:NYRADA PTY LTD

Transient receptor potential melastatin 8 agonist-containing ocular conditions and uses thereof

The present application provides compositions and methods for treating ocular conditions (e.g., dry eye syndrome, dry eye disease, keratoconjunctivitis sicca, inflammatory dry eye, redness, or meibomian gland dysfunction). The compositions can comprise a transient receptor potential melastatin 8 (TRPM8) agonist (e.g., menthol or AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide)) and a semi-fluorinated alkane compound; or can comprise a TRPM8 agonist (e.g., menthol AR-15512 ((1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl) cyclohexanecarboxamide)), a semi-fluorinated alkane compound. The compositions can confer chemical stability of the TRPM8 agonist.
Owner:ADS THERAPEUTICS LLC

Vagus nerve double-targeting delivery carrier as well as preparation method and application thereof

PendingCN122005851AAchieve high spatial and temporal resolution controlLess invasiveNervous disorderMetabolism disorderTransient receptor potential channelNir light
The invention discloses a vagus nerve double-targeting delivery carrier as well as a preparation method and application thereof. According to the vagus nerve double-targeting delivery carrier, the surface of a nano carrier is simultaneously modified with a first targeting ligand capable of being combined with a nicotinic acetylcholine receptor on the surface of vagus nerve cells and a second targeting ligand capable of being specifically combined with a transient receptor potential channel. The enrichment efficiency and the spatial selectivity of the photoresponse nano-carrier in the vagus nerve area are effectively improved through a targeting delivery strategy of lymphatic path guidance and double receptor molecule recognition, the specific targeting of the photoresponse nano-carrier to the vagus nerve is enhanced, and in the follow-up NIR light irradiation process, the photoresponse nano-carrier has a good application prospect. Effective activation of the vagus nerve can be realized under lower optical power density, non-specific stimulation to surrounding non-target tissues is remarkably reduced, and safety and accuracy of light regulation of the vagus nerve are improved.
Owner:SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI